The stock was up 31 percent at the time of publication at $4.97.
Achieve Life Sciences announced that its cytisine produced positive study results when evaluated as a smoking cessation treatment option.
Cytisine is a plant-based alkaloid which binds to the nicotinic acetylcholine receptor, according to the company.
The results were based on a series of drug metabolism, drug-to-drug interaction and transponder studies.
Why It's Important
The pipeline candidate can be administered without modifying the dose of the co-administered drug.
"We are very pleased with the results of these detailed studies. Smokers are as likely as anyone to take medications for a range of conditions. These results suggest that cytisine is unlikely to interfere with their ability to take other medications safely, and should help to minimize restrictions on the eligibility of subjects in our forthcoming clinical trials," Chief Scientific Officer Anthony Clarke said in a statement.
Two previous Phase 3 studies, dubbed TASC and CASCAID, in which a total of 2,000 patients were enrolled, produced favorable outcomes, according to Achieve.
The company plans to initiate further clinical trials later this year.
FDA Approves Achaogen's Antibiotic For Urinary Tract Infection, But Issues CRL For Bloodstream Infections
The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs
See more from Benzinga
- Benzinga's Daily Biotech Pulse: Sarepta's DMD Gene Therapy, Anika's Flunked Trial, Eidos To Commence Trading
- Benzinga's Daily Biotech Pulse: Biohaven Sells Right To Drug, Obseva To Sell Shares
- Benzinga's Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid Addiction Drug
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.